B-TEMIA and Myositis Canada Join Forces to Raise Awareness About Myositis and the Dermoskeleton™ Technology

QUÉBEC CITY, Québec, May 08, 2017 (GLOBE NEWSWIRE) -- B-TEMIA Inc., a leader in the human augmentation market with its proprietary dermoskeletal technology, and Myositis Canada, a volunteer charitable organization dedicated to improving the lives of people affected by Myositis, announce today that they will collaborate to raise awareness of both Myositis and the Dermoskeleton™ powered walking assistance technology developed by B-Temia.

A photo accompanying this announcement is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/48bd5258-ac93-4f57-8c7f-7bb8f12fa243

Myositis is a rare but debilitating muscle disease that can result in rapid and tragic muscle loss, and hence mobility limitations. In recent trials with patients affected by Myositis, B-Temia’s Dermoskeleton™ has shown to enhance mobility capacities.

“B-Temia’s Dermoskeleton™ was developed to help individuals with mobility limitations due to diseases such as Myositis. We are very pleased to collaborate with Myositis Canada and contribute to the awareness of this rare condition,” stated Stéphane Bédard, CEO of B-TEMIA.

“We are proud of collaborating with a company like B-Temia that developed a great technology that has the potential to benefit many individuals with Myositis. Joining forces will be a win-win combination to raise awareness of both the Dermoskeleton™ and Myositis,” added Herb Malcomson, President of Myositis Canada.

Man with Myositis to take part in the 10K at the Ottawa run on May 27
Martin Jarry, a policeman and hockey coach, was diagnosed with Myositis a year ago at the age of 46. He has since embarked on a journey to dramatically increase awareness about Myositis. On May 27, he will run the 10K in Ottawa to raise funds for Myositis Canada. To accomplish his goal, he is training every day, and he will be wearing B-Temia’s Dermoskeleton™, without which it would be impossible for him to complete the run.

“May is the month of Myositis. Team up with me in Ottawa, and help me raise money so we can help diagnose and treat Myositis,” said Martin Jarry.               

To donate to Myositis Canada via the Ottawa run: https://secure.e2rm.com/registrant/TeamFundraisingPage.aspx?EventID=205275&LangPref=en-CA&TeamID=737427

About the Keeogo^TM Dermokeleton™
Keeogo^TM is a powered walking assistance device developed by B-TEMIA. It has been used by individuals with degenerative medical conditions such as knee/hip osteoarthritis, multiple sclerosis, Parkinson’s disease, stroke, incomplete spinal cord injury (SCI) and other conditions that limit mobility. Used as rehabilitation equipment or as a daily commodity for walking, Keeogo^TM is commercially available in Canada for purchase or rental. It is currently under investigation in a multicenter pivotal clinical trial aiming for Food and Drug Administration (FDA) clearance, a prerequisite to enter the US market.

About Myositis
The word Myositis literally means inflammation of muscle; it describes inflammation or swelling of the muscle tissue that can result in rapid and tragic muscle loss. This can be caused by infection, injury, certain medicines, and chronic disease. There are a number of types of Myositis; they include:

• DermatoMyositis (DM)
• Inclusion-Body Myositis (IBM)
• Juvenile forms of Myositis (JM)
• PolyMyositis (PM)

About B-TEMIA
Founded in 2010, B-TEMIA Inc. is a medical device manufacturer that develops and markets cutting-edge products for the growing market of human augmentation systems. B-TEMIA operates through two wholly-owned subsidiaries, B-TEMIA Inc. and B-TEMIA USA Inc., in the medical, industrial and military fields. B-TEMIA owns a patented technology called Dermoskeleton^TM that restores, maintains or enhances the mobility of users.

About Myositis Canada
Myositis Canada is a non-profit, volunteer organization dedicated to improving the lives of people affected by Myositis. Formed in 2015, Myositis Canada is governed by a volunteer Board of Directors that includes patients, family members and interested professionals, bringing diverse strengths and perspectives to the organization. The organization achieved charitable status from the Canada Revenue Agency (CRA) on December 2, 2015. For more information: www.Myositis.ca

Information